Histocompatibility methods

Transplantation Reviews

Volumn 23, Issue 2, 2009, Pages 80-93

  Tinckam, Kathryn ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; HLA A ANTIGEN; HLA A1 ANTIGEN; HLA A2 ANTIGEN; HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA B7 ANTIGEN; HLA B8 ANTIGEN; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT;

ALLOIMMUNITY; ANTIBODY SCREENING; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; COMPLEMENT DEPENDENT CYTOTOXICITY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TEST; HLA MATCHING; HLA TYPING; HUMAN; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; MOLECULAR TYPING; ORGAN TRANSPLANTATION; POSTOPERATIVE PERIOD; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE;

EID: 61949296819     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2009.01.001     Document Type: Article

References (153)

1. Patel R., and Terasaki P.I. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 280 (1969) 735-739
2. Arnold M.L., Pei R., Spriewald B., and Wassmuth R. Anti-HLA class II antibodies in kidney retransplant patients. Tissue Antigens 65 (2005) 370-378
3. Muczynski K.A., Ekle D.M., Coder D.M., and Anderson S.K. Normal human kidney HLA-DR-expressing renal microvascular endothelial cells: characterization, isolation, and regulation of MHC class II expression. J Am Soc Nephrol 14 (2003) 1336-1348
4. von Andrian U.H., and Mackay C.R. T-cell function and migration. Two sides of the same coin. N Engl J Med 343 (2000) 1020-1034
5. Ono S.J., Nakamura T., Miyazaki D., Ohbayashi M., Dawson M., and Toda M. Chemokines: roles in leukocyte development, trafficking, and effector function. J Allergy Clin Immunol 111 (2003) 1185-1199 [quiz 200]
6. von Andrian U.H., and Mempel T.R. Homing and cellular traffic in lymph nodes. Nat Rev Immunol 3 (2003) 867-878
7. Cyster J.G. Homing of antibody secreting cells. Immunol Rev 194 (2003) 48-60
8. Zinkernagel R.M., and Doherty P.C. The discovery of MHC restriction. Immunol Today 18 (1997) 14-17
9. Huppa J.B., and Davis M.M. T-cell-antigen recognition and the immunological synapse. Nat Rev Immunol 3 (2003) 973-983
10. Jacobelli J., Andres P.G., Boisvert J., and Krummel M.F. New views of the immunological synapse: variations in assembly and function. Curr Opin Immunol 16 (2004) 345-352
11. Scholl P.R., and Geha R.S. MHC class II signaling in B-cell activation. Immunol Today 15 (1994) 418-422
12. Kumanogoh A., Watanabe C., Lee I., et al. Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: a novel mechanism for regulating B cell signaling. Immunity 13 (2000) 621-631
13. Sharpe A.H., and Freeman G.J. The B7-CD28 superfamily. Nat Rev Immunol 2 (2002) 116-126
14. Bishop G.A., and Hostager B.S. The CD40-CD154 interaction in B cell-T cell liaisons. Cytokine Growth Factor Rev 14 (2003) 297-309
15. Coyle A.J., Lehar S., Lloyd C., et al. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity 13 (2000) 95-105
16. Kato H., Kojima H., Ishii N., et al. Essential role of OX40L on B cells in persistent alloantibody production following repeated alloimmunizations. J Clin Immunol 24 (2004) 237-248
17. DeBenedette M.A., Wen T., Bachmann M.F., et al. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus. J Immunol 163 (1999) 4833-4841
18. Prodinger W.M., Wurzner R., Stoiber H., and Dierich M.P. Complement. In: Paul W.E. (Ed). Fundamentals in immunology (2003), Lippincott Williams & Wilkins, Philadelphia 1077-1103
19. Schreuder G.M., Hurley C.K., Marsh S.G., et al. HLA dictionary 2004: summary of HLA-A, -B, -C, -DRB1/3/4/5, -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR, and -DQ antigens. Hum Immunol 66 (2005) 170-210
20. Robinson J., Waller M.J., Parham P., et al. IMGT/HLA and IMGT/MHC: sequence databases for the study of the major histocompatibility complex. Nucleic Acids Res 31 (2003) 311-314
21. Claas F.H., Witvliet M.D., Duquesnoy R.J., Persijn G.G., and Doxiadis I.I.N. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome. Transplantation 78 (2004) 190-193
22. Duquesnoy R.J., and Askar M. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ, and HLA-DP. Hum Immunol 68 (2007) 12-25
23. Duquesnoy R.J., and Claas F.H. Is the application of HLAMatchmaker relevant in kidney transplantation?. Transplantation 79 (2005) 250-251
24. Duquesnoy R.J., and Claas F.H. 14th International HLA and Immunogenetics Workshop: report on the structural basis of HLA compatibility. Tissue Antigens 69 Suppl 1 (2007) 180-184
25. Duquesnoy R.J., Mulder A., Askar M., Fernandez-Vina M., and Claas F.H. HLAMatchmaker-based analysis of human monoclonal antibody reactivity demonstrates the importance of an additional contact site for specific recognition of triplet-defined epitopes. Hum Immunol 66 (2005) 749-761
26. Claas F.H., Roelen D.L., Oudshoorn M., and Doxiadis I.I.N. Future HLA matching strategies in clinical transplantation. Dev Ophthalmol 36 (2003) 62-73
27. Claas F.H. Predictive parameters for in vivo alloreactivity. Transpl Immunol 10 (2002) 137-142
28. Marsh S.G. Nomenclature for factors of the HLA system monthly updates 2006-2008 (2008). http://www.anthonynolan.com/HIG/nomen/updates/updates.html
29. Cecka J.M., and Terasaki P.I. The UNOS scientific renal transplant registry. United Network for Organ Sharing. Clin Transpl (1995) 1-18
30. Takemoto S., Terasaki P.I., Cecka J.M., Cho Y.W., and Gjertson D.W. Survival of nationally shared, HLA-matched kidney transplants from cadaveric donors. The UNOS Scientific Renal Transplant Registry. N Engl J Med 327 (1992) 834-839
31. Opelz G. Influence of HLA matching on survival of second kidney transplants in cyclosporine-treated recipients. Transplantation 47 (1989) 823-827
32. Opelz G., Mickey M.R., and Terasaki P.I. HLA matching and cadaver kidney transplant survival in North America: influence of center variation and presensitization. Transplantation 23 (1977) 490-497
33. Wissing K.M., Fomegne G., Broeders N., et al. HLA mismatches remain risk factors for acute kidney allograft rejection in patients receiving quadruple immunosuppression with anti-interleukin-2 receptor antibodies. Transplantation 85 (2008) 411-416
34. Opelz G., Wujciak T., Dohler B., Scherer S., and Mytilineos J. HLA compatibility and organ transplant survival. Collaborative Transplant Study. Rev Immunogenet 1 (1999) 334-342
35. Opelz G., and Dohler B. Multicenter analysis of kidney preservation. Transplantation 83 (2007) 247-253
36. Fuller A., Profaizer T., Roberts L., and Fuller T.C. Repeat donor HLA-DR mismatches in renal transplantation: is the increased failure rate caused by noncytotoxic HLA-DR alloantibodies?. Transplantation 68 (1999) 589-591
37. House A.A., Chang P.C., Luke P.P., et al. Re-exposure to mismatched HLA class I is a significant risk factor for graft loss: multivariable analysis of 259 kidney retransplants. Transplantation 84 (2007) 722-728
38. Lair D., Coupel S., Giral M., et al. The effect of a first kidney transplant on a subsequent transplant outcome: an experimental and clinical study. Kidney Int 67 (2005) 2368-2375
39. Gjertson D.W. A multi-factor analysis of kidney regraft outcomes. Clin Transpl (2002) 335-349
40. Crowe D.O. The effect of cross-reactive epitope group matching on allocation and sensitization. Clin Transplant 17 Suppl 9 (2003) 13-16
41. Thompson J.S., Thacker II L.R., and Takemoto S. The influence of conventional and cross-reactive group HLA matching on cardiac transplant outcome: an analysis from the United Network of Organ Sharing Scientific Registry. Transplantation 69 (2000) 2178-2186
42. Gentry S.E., Segev D.L., Simmerling M., and Montgomery R.A. Expanding kidney paired donation through participation by compatible pairs. Am J Transplant 7 (2007) 2361-2370
43. Kaplan I., Houp J.A., Montgomery R.A., Leffell M.S., Hart J.M., and Zachary A.A. A computer match program for paired and unconventional kidney exchanges. Am J Transplant 5 (2005) 2306-2308
44. Segev D.L., Gentry S.E., Warren D.S., Reeb B., and Montgomery R.A. Kidney paired donation and optimizing the use of live donor organs. JAMA 293 (2005) 1883-1890
45. Bray R.A., and Gebel H.M. Allele specific HLA alloantibodies. Implication for organ allocation. Am J Transplant 5 (2005) 488
46. Gebel H.M., Bray R.A., and Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant 3 (2003) 1488-1500
47. Gebel H.M., and Bray R.A. Laboratory assessment of HLA antibodies circa 2006: making sense of sensitivity. Transpl Rev 20 (2006) 189-194
48. Mizutani K., Terasaki P., Rosen A., et al. Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant 5 (2005) 2265-2272
49. Zou Y., Stastny P., Susal C., Dohler B., and Opelz G. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 357 (2007) 1293-1300
50. Tran T.H., Mytilineos J., Scherer S., Laux G., Middleton D., and Opelz G. Analysis of KIR ligand incompatibility in human renal transplantation. Transplantation 80 (2005) 1121-1123
51. van den Berg-Loonen E.M., Billen E.V., Voorter C.E., et al. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation 85 (2008) 1086-1090
52. Gupta A., Iveson V., Varagunam M., Bodger S., Sinnott P., and Thuraisingham R.C. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant?. Transplantation 85 (2008) 1200-1204
53. Stegall M.D., Gloor J., Winters J.L., Moore S.B., and Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 6 (2006) 346-351
54. Jordan S.C., Vo A.A., Nast C.C., and Tyan D. Use of high-dose human intravenous immunoglobulin therapy in sensitized patients awaiting transplantation: the Cedars-Sinai experience. Clin Transpl (2003) 193-198
55. Gebel H.M., and Bray R.A. Sensitization and sensitivity: defining the unsensitized patient. Transplantation 69 (2000) 1370-1374
56. Zachary A.A., Delaney N.L., Lucas D.P., and Leffell M.S. Characterization of HLA class I specific antibodies by ELISA using solubilized antigen targets: I. Evaluation of the GTI QuikID assay and analysis of antibody patterns. Hum Immunol 62 (2001) 228-235
57. Zachary A.A., Ratner L.E., Graziani J.A., Lucas D.P., Delaney N.L., and Leffell M.S. Characterization of HLA class I specific antibodies by ELISA using solubilized antigen targets: II. Clinical relevance. Hum Immunol 62 (2001) 236-246
58. Kao K.J., Scornik J.C., and Small S.J. Enzyme-linked immunoassay for anti-HLA antibodies-an alternative to panel studies by lymphocytotoxicity. Transplantation 55 (1993) 192-196
59. Pei R., Lee J., Chen T., Rojo S., and Terasaki P.I. Flow cytometric detection of HLA antibodies using a spectrum of microbeads. Hum Immunol 60 (1999) 1293-1302
60. Pei R., Wang G., Tarsitani C., et al. Simultaneous HLA class I and class II antibodies screening with flow cytometry. Hum Immunol 59 (1998) 313-322
61. Pei R., Lee J.H., Shih N.J., Chen M., and Terasaki P.I. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 75 (2003) 43-49
62. Campbell P., Bray R.A., Eckels D., and Gebel H.M. Standardization of HLA antibody identification across multiple laboratories. Is it feasible?. Hum Immunol 68 (2007) s117
63. Vaidya S. Clinical importance of anti-human leukocyte antigen-specific antibody concentration in performing calculated panel reactive antibody and virtual crossmatches. Transplantation 85 (2008) 1046-1050
64. Mizutani K., Terasaki P., Hamdani E., et al. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant 7 (2007) 1027-1031
65. Opelz G., and Terasaki P.I. Recipient selection for renal retransplantation. Transplantation 21 (1976) 483-488
66. Opelz G. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 365 (2005) 1570-1576
67. Gebel H.M., Bray R.A., Ruth J.A., et al. Flow PRA to detect clinically relevant HLA antibodies. Transplant Proc 33 (2001) 477
68. Bray R.A., Nolen J.D., Larsen C., et al. Transplanting the highly sensitized patient: the Emory algorithm. Am J Transplant 6 (2006) 2307-2315
69. Bryan C.F., McDonald S.B., Luger A.M., et al. Successful renal transplantation despite low levels of donor-specific HLA class I antibody without IVIg or plasmapheresis. Clin Transplant 20 (2006) 563-570
70. Patel A.M., Pancoska C., Mulgaonkar S., and Weng F.L. Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant 7 (2007) 2371-2377
71. Stiller C.R., Sinclair N.R., Abrahams S., Ulan R.A., Fung M., and Wallace A.C. Lymphocyte-dependent antibody and renal graft rejection. Lancet 1 (1975) 953-954
72. Amos D.B., Cohen I., and Klein Jr. W.J. Mechanisms of immunologic enhancement. Transplant Proc 2 (1970) 68-75
73. Cross D.E., Whittier F.C., Weaver P., and Foxworth J. A comparison of the antiglobulin versus extended incubation time crossmatch: results in 223 renal transplants. Transplant Proc 9 (1977) 1803-1806
74. Johnson A.H., Rossen R.D., and Butler W.T. Detection of alloantibodies using a sensitive antiglobulin microcytotoxicity test: identification of low levels of pre-formed antibodies in accelerated allograft rejection. Tissue Antigens 2 (1972) 215-226
75. Ting A., Hasegawa T., Ferrone S., and Reisfeld R.A. Presensitization detected by sensitive crossmatch tests. Transplant Proc 5 (1973) 813-817
76. Fuller T.C., Cosimi A.B., and Russell P.S. Use of an antiglobulin-ATG reagent for detection of low levels of alloantibody-improvement of allograft survival in presensitized recipients. Transplant Proc 10 (1978) 463-466
77. Fuller T.C., Phelan D., Gebel H.M., and Rodey G.E. Antigenic specificity of antibody reactive in the antiglobulin-augmented lymphocytotoxicity test. Transplantation 34 (1982) 24-29
78. Kerman R.H., Kimball P.M., Van Buren C.T., et al. AHG and DTE/AHG procedure identification of crossmatch-appropriate donor-recipient pairings that result in improved graft survival. Transplantation 51 (1991) 316-320
79. Fuller T.C., Fuller A.A., Golden M., and Rodey G.E. HLA alloantibodies and the mechanism of the antiglobulin-augmented lymphocytotoxicity procedure. Hum Immunol 56 (1997) 94-105
80. Gebel H.M., Oldfather J.W., Karr R.W., Fuller T.C., and Rodey G.E. Antibodies directed against HLA-DR gene products exhibit the CYNAP phenomenon. Tissue Antigens 23 (1984) 135-140
81. Garovoy M.R., Rheinschmilt M.A., Bigos M., et al. Flow Cytometry Analysis: a high technology crossmatch technique facilitatin transplantation. Transplant Proc 15 (1983) 1939-1944
82. Bray R.A., Lebeck L.K., and Gebel H.M. The flow cytometric crossmatch. Dual-color analysis of T cell and B cell reactivities. Transplantation 48 (1989) 834-840
83. Scornik J.C., Brunson M.E., Schaub B., Howard R.J., and Pfaff W.W. The crossmatch in renal transplantation. Evaluation of flow cytometry as a replacement for standard cytotoxicity. Transplantation 57 (1994) 621-625
84. Scornik J.C., Clapp W., Patton P.R., et al. Outcome of kidney transplants in patients known to be flow cytometry crossmatch positive. Transplantation 71 (2001) 1098-1102
85. Scornik J.C., Bray R.A., Pollack M.S., et al. Multicenter evaluation of the flow cytometry T-cell crossmatch: results from the American Society of Histocompatibility and Immunogenetics-College of American Pathologists proficiency testing program. Transplantation 63 (1997) 1440-1445
86. Cross D.E., Greiner R., and Whittier F.C. Importance of the autocontrol crossmatch in human renal transplantation. Transplantation 21 (1976) 307-311
87. Ting A., and Morris P.J. Renal transplantation and B-cell cross-matches with autoantibodies and alloantibodies. Lancet 2 (1977) 1095-1097
88. Ettenger R.B., Jordan S.C., and Fine R.N. Cadaver renal transplant outcome in recipients with autolymphocytotoxic antibodies. Transplantation 35 (1983) 429-431
89. Chapman J.R., Ting A., Fisher M., Carter N.P., and Morris P.J. Failure of platelet transfusion to improve human renal allograft survival. Transplantation 41 (1986) 468-473
90. Taylor C.J., Chapman J.R., Ting A., and Morris P.J. Characterization of lymphocytotoxic antibodies causing a positive crossmatch in renal transplantation. Relationship to primary and regraft outcome. Transplantation 48 (1989) 953-958
91. Vaidya S., and Ruth J. Contributions and clinical significance of IgM and autoantibodies in highly sensitized renal allograft recipients. Transplantation 47 (1989) 956-958
92. Bryan C.F., Martinez J., Muruve N., et al. IgM antibodies identified by a DTT-ameliorated positive crossmatch do not influence renal graft outcome but the strength of the IgM lymphocytotoxicity is associated with DR phenotype. Clin Transplant 15 Suppl 6 (2001) 28-35
93. Mauiyyedi S., Crespo M., Collins A.B., et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 13 (2002) 779-787
94. Jurcevic S., Ainsworth M.E., Pomerance A., et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 71 (2001) 886-892
95. Sumitran-Holgersson S., Wilczek H.E., Holgersson J., and Soderstrom K. Identification of the nonclassical HLA molecules, mica, as targets for humoral immunity associated with irreversible rejection of kidney allografts. Transplantation 74 (2002) 268-277
96. Ferry B.L., Welsh K.I., Dunn M.J., et al. Anti-cell surface endothelial antibodies in sera from cardiac and kidney transplant recipients: association with chronic rejection. Transpl Immunol 5 (1997) 17-24
97. Ball B., Mousson C., Ratignier C., Guignier F., Glotz D., and Rifle G. Antibodies to vascular endothelial cells in chronic rejection of renal allografts. Transplant Proc 32 (2000) 353-354
98. Bray R.A., Nickerson P.W., Kerman R.H., and Gebel H.M. Evolution of HLA antibody detection: technology emulating biology. Immunol Res 29 (2004) 41-54
99. Le Bas-Bernardet S., Hourmant M., Valentin N., et al. Identification of the antibodies involved in B-cell crossmatch positivity in renal transplantation. Transplantation 75 (2003) 477-482
100. Roelen D.L., van Bree J., Witvliet M.D., et al. IgG antibodies against an HLA antigen are associated with activated cytotoxic T cells against this antigen, IgM are not. Transplantation 57 (1994) 1388-1392
101. Spees E., and McCalmon R. Successful kidney transplantation with a positive IgM crossmatch. Transplant Proc 22 (1990) 1887-1888
102. McCalmon Jr. R.T., Tardif G.N., Sheehan M.A., Fitting K., Kortz W., and Kam I. IgM antibodies in renal transplantation. Clin Transplant 11 (1997) 558-564
103. Tardif G.N., and McCalmon Jr. R.T. Successful renal transplantation in the presence of donor specific HLA IgM antibodies. Transplant Proc 27 (1995) 664-665
104. Iwaki Y., Cook D.J., Terasaki P.I., et al. Flow cytometry crossmatching in human cadaver kidney transplantation. Transplant Proc 19 (1987) 764-766
105. Cook D.J., Terasaki P.I., Iwaki Y., et al. The flow cytometry crossmatch in kidney transplantation. Clin Transpl (1987) 409-414
106. Mahoney R.J., Ault K.A., Given S.R., et al. The flow cytometric crossmatch and early renal transplant loss. Transplantation 49 (1990) 527-535
107. Kerman R.H., Van Buren C.T., Lewis R.M., et al. Improved graft survival for flow cytometry and antihuman globulin crossmatch-negative retransplant recipients. Transplantation 49 (1990) 52-56
108. Ogura K., Terasaki P.I., Johnson C., et al. The significance of a positive flow cytometry crossmatch test in primary kidney transplantation. Transplantation 56 (1993) 294-298
109. Karpinski M., Rush D., Jeffery J., et al. Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol 12 (2001) 2807-2814
110. Bryan C.F., Baier K.A., Nelson P.W., et al. Long-term graft survival is improved in cadaveric renal retransplantation by flow cytometric crossmatching. Transplantation 66 (1998) 1827-1832
111. Kerman R.H., Gebel H.M., and Bray R.A. HLA antibody and donor reactivity define patients at risk for rejection or graft loss. Am J Transplant (2002) 258
112. Ettinger R.B., Terasaki P.I., Opelz G., et al. Successful renal allografts across a positive cross-match for donor B-lymphocyte alloantigens. Lancet 2 (1976) 56-58
113. Sirchia G., Mercuriali F., Scalamogna M., et al. Preexistent anti-HLA-DR antibodies and kidney graft survival. Transplant Proc 11 (1979) 950-953
114. Ayoub G., Park M.S., Terasaki P.I., Iwaki Y., and Opelz G. B cell antibodies and crossmatching. Transplantation 29 (1980) 227-229
115. Mohanakumar T., Rhodes C., Mendez-Picon G., Goldman M., Moncure C., and Lee H. Renal allograft rejection associated with presensitization to HLA-DR antigens. Transplantation 31 (1981) 93-95
116. Jeannet M., Benzonana G., and Arni I. Donor-specific B and T lymphocyte antibodies and kidney graft survival. Transplantation 31 (1981) 160-163
117. Russ G.R., Nicholls C., Sheldon A., and Hay J. Positive B lymphocyte crossmatch and glomerular rejection in renal transplant recipients. Transplant Proc 19 (1987) 785-788
118. Noreen H.J., van der Hagen E., Bach F.H., Najarian J.S., and Fryd D.S. Renal allograft survival in CSA-treated patients with positive donor-specific B cell crossmatches. Transplant Proc 21 (1989) 691-692
119. Phelan D.L., Rodey G.E., Flye M.W., Hanto D.W., Anderson C.B., and Mohanakumar T. Positive B cell crossmatches: specificity of antibody and graft outcome. Transplant Proc 21 (1989) 687-688
120. Pellegrino M.A., Belvedere M., Pellegrino A.G., and Ferrone S. B peripheral lymphocytes express more HLA antigens than T peripheral lymphocytes. Transplantation 25 (1978) 93-95
121. Karuppan S.S., Lindholm A., and Moller E. Characterization and significance of donor-reactive B cell antibodies in current sera of kidney transplant patients. Transplantation 49 (1990) 510-515
122. Mahoney R.J., Taranto S., and Edwards E. B-Cell crossmatching and kidney allograft outcome in 9031 United States transplant recipients. Hum Immunol 63 (2002) 324-335
123. Turka L.A., Goguen J.E., Gagne J.E., and Milford E.L. Presensitization and the renal allograft recipient. Transplantation 47 (1989) 234-240
124. Bryan C.F., Shield C.F., Warady B.A., et al. Influence of an historically positive crossmatch on cadaveric renal transplantation. Transplant Proc 31 (1999) 225-227
125. Saw C.L., Bray R.A., and Gebel H.M. Cytotoxicity and antibody binding by flow cytometry: a single assay to simultaneously assess two parameters. Cytometry B Clin Cytom (2008)
126. Won D.I., Jeong H.D., Kim Y.L., and Suh J.S. Simultaneous detection of antibody binding and cytotoxicity in flow cytometry crossmatch for renal transplantation. Cytometry B Clin Cytom 70 (2006) 82-90
127. Schonemann C., Lachmann N., Kiesewetter H., and Salama A. Flow cytometric detection of complement-activating HLA antibodies. Cytometry B Clin Cytom 62 (2004) 39-45
128. Smith J.D., Hamour I.M., Banner N.R., and Rose M.L. C4d fixing, luminex binding antibodies-a new tool for prediction of graft failure after heart transplantation. Am J Transplant 7 (2007) 2809-2815
129. Yang C.W., Oh E.J., Lee S.B., et al. Detection of donor-specific anti-HLA class I and II antibodies using antibody monitoring system. Transplant Proc 38 (2006) 2803-2806
130. Fernandez-Fresnedo G., Pastor J.M., Lopez-Hoyos M., et al. Relationship of donor-specific class-I anti-HLA antibodies detected by ELISA after kidney transplantation on the development of acute rejection and graft survival. Nephrol Dial Transplant 18 (2003) 990-995
131. Altermann W.W., Seliger B., Sel S., Wendt D., and Schlaf G. Comparison of the established standard complement-dependent cytotoxicity and flow cytometric crossmatch assays with a novel ELISA-based HLA crossmatch procedure. Histol Histopathol 21 (2006) 1115-1124
132. Book B.K., Agarwal A., Milgrom A.B., et al. New crossmatch technique eliminates interference by humanized and chimeric monoclonal antibodies. Transplant Proc 37 (2005) 640-642
133. Wahrmann M., Exner M., Schillinger M., et al. Pivotal role of complement-fixing HLA alloantibodies in presensitized kidney allograft recipients. Am J Transplant 6 (2006) 1033-1041
134. Billen E.V., Voorter C.E., Christiaans M.H., and van den Berg-Loonen E.M. Luminex donor-specific crossmatches. Tissue Antigens 71 (2008) 507-513
135. Najafian N., Salama A.D., Fedoseyeva E.V., Benichou G., and Sayegh M.H. Enzyme-linked immunosorbent spot assay analysis of peripheral blood lymphocyte reactivity to donor HLA-DR peptides: potential novel assay for prediction of outcomes for renal transplant recipients. J Am Soc Nephrol 13 (2002) 252-259
136. Heeger P.S., Greenspan N.S., Kuhlenschmidt S., et al. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol 163 (1999) 2267-2275
137. Nickel P., Presber F., Bold G., et al. Enzyme-linked immunosorbent spot assay for donor-reactive interferon-gamma-producing cells identifies T-cell presensitization and correlates with graft function at 6 and 12 months in renal-transplant recipients. Transplantation 78 (2004) 1640-1646
138. Andree H., Nickel P., Nasiadko C., et al. Identification of dialysis patients with panel-reactive memory T cells before kidney transplantation using an allogeneic cell bank. J Am Soc Nephrol 17 (2006) 573-580
139. Poggio E.D., Clemente M., Hricik D.E., and Heeger P.S. Panel of reactive T cells as a measurement of primed cellular alloimmunity in kidney transplant candidates. J Am Soc Nephrol 17 (2006) 564-572
140. Kowalski R.J., Post D.R., Mannon R.B., et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 82 (2006) 663-668
141. Chan K.W., Hopke C.D., Krams S.M., and Martinez O.M. CD30 expression identifies the predominant proliferating T lymphocyte population in human alloimmune responses. J Immunol 169 (2002) 1784-1791
142. Pelzl S., Opelz G., Wiesel M., et al. Soluble CD30 as a predictor of kidney graft outcome. Transplantation 73 (2002) 3-6
143. Susal C., Pelzl S., Dohler B., and Opelz G. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 13 (2002) 1650-1656
144. Bierl C., Miller B., Prak E.L., et al. Antibody-mediated rejection in heart transplant recipients: potential efficacy of B-cell depletion and antibody removal. Clin Transpl (2006) 489-496
145. Xydas S., Yang J.K., Burke E.M., et al. Utility of post-transplant anti-HLA antibody measurements in pediatric cardiac transplant recipients. J Heart Lung Transplant 24 (2005) 1289-1296
146. Hadjiliadis D., Chaparro C., Reinsmoen N.L., et al. Pre-transplant panel reactive antibody in lung transplant recipients is associated with significantly worse post-transplant survival in a multicenter study. J Heart Lung Transplant 24 (2005) S249-S254
147. Girnita A.L., Duquesnoy R., Yousem S.A., et al. HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant 5 (2005) 131-138
148. Girnita A.L., McCurry K.R., Iacono A.T., et al. HLA-specific antibodies are associated with high-grade and persistent-recurrent lung allograft acute rejection. J Heart Lung Transplant 23 (2004) 1135-1141
149. Halloran P.F., Schlaut J., Solez K., and Srinivasa N.S. The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 53 (1992) 550-555
150. Halloran P.F., Wadgymar A., Ritchie S., Falk J., Solez K., and Srinivasa N.S. The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation 49 (1990) 85-91
151. Terasaki P.I., and Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 4 (2004) 438-443
152. Piazza A., Poggi E., Borrelli L., et al. Impact of donor-specific antibodies on chronic rejection occurrence and graft loss in renal transplantation: posttransplant analysis using flow cytometric techniques. Transplantation 71 (2001) 1106-1112
153. Pelletier R.P., Hennessy P.K., Adams P.W., VanBuskirk A.M., Ferguson R.M., and Orosz C.G. Clinical significance of MHC-reactive alloantibodies that develop after kidney or kidney-pancreas transplantation. Am J Transplant 2 (2002) 134-141